Peer-Reviewed Medical & Scientific Research, Open to the World

Its published work so far comes mainly from gastroenterology and hepatology, neurology, immunology, and diabetes and endocrinology, with smaller groups of papers in cardiology, surgery and orthopaedics, dentistry and maxillofacial research, and nursing and medical education. TJOCM publishes original clinical studies, narrative reviews, case reports and case series. Recent examples include a real-world evaluation of a diosmectite-based device for diarrhoea, a longitudinal multiomics study of cerebrospinal fluid in cognitive impairment, a national multicentre cohort on chronic kidney disease progression after SARS-CoV-2 infection, and a case series on myasthenia gravis. The journal is a good fit for clinicians who want to report what they observe in everyday practice — an unusual presentation, an audit of a ward population or an evaluation of a teaching method — as well as for formal observational studies. Manuscripts are assessed by double-blind peer review. Articles are published open access under a CC BY 4.0 licence, with copyright kept by the authors. The journal follows COPE ethical principles and is committed to transparency and integrity. An article-processing charge applies on acceptance, with waivers and discounts available to ensure equitable access to publication.

Advances scholarship across the full spectrum of cardiology and cardiovascular medicine, from molecular mechanisms of atherosclerosis to evidence that shapes bedside practice. JOCD welcomes original research, systematic reviews and meta-analyses, clinical case reports, and editorials spanning heart failure, coronary artery disease, myocardial infarction, arrhythmia and electrophysiology, interventional and surgical cardiology, preventive cardiology, lipid disorders, and cardiac rehabilitation. We encourage translational work connecting biomechanics, imaging, pharmacotherapy, and exercise therapy to measurable patient outcomes. Every submission undergoes rigorous double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright. The journal follows COPE ethical principles and applies an article-processing charge on acceptance, with waivers and discounts available to ensure equitable access for all authors.

Dedicated to advancing clinical, translational, and surgical cancer research. The journal serves oncologists, hematologists, surgical and radiation oncologists, cancer biologists, and translational scientists with rigorous, internationally accessible scholarship across the cancer continuum, from molecular pathogenesis to diagnosis, treatment, and survivorship. We welcome original research, systematic reviews and meta-analyses, case reports, and editorials spanning tumor biology, cancer biomarkers and liquid biopsy (circulating tumor DNA, cell-free DNA, microRNAs), molecular cytogenetics, hematological malignancies (multiple myeloma, DLBCL and other lymphomas), surgical and interventional oncology, pediatric oncology, translational pharmacology including phytochemical and inflammasome research, and emerging artificial intelligence applications in cancer screening and diagnostics. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright. The journal adheres to COPE ethical principles and supports global research equity through article-processing-charge waivers and discounts, ensuring authors from all regions can disseminate high-impact cancer research to a worldwide readership.

Advances scholarship across epidemiology, infectious disease and immunization, health policy and systems, environmental and occupational health, and maternal, child and behavioral health, serving researchers, clinicians, epidemiologists, and policymakers worldwide. TAJOPH publishes original research, systematic and narrative reviews, case reports, short communications, and editorials. We particularly welcome work on disease surveillance, vaccine confidence and immunization, antimicrobial resistance, non-communicable disease prevention, social determinants of health, and the population-level lessons of COVID-19 and other public health emergencies. Emphasis is placed on methodological rigor and translational relevance, from quantitative epidemiology and risk-prediction modeling to qualitative and health-systems research that informs policy and practice across high-, middle-, and low-resource settings. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) license with authors retaining copyright. The journal follows COPE ethical principles, with article-processing charges applied on acceptance and waivers available.

Most of its published papers so far examine host responses to viruses and mycobacteria — SARS-CoV-2 and post-COVID syndrome, chronic hepatitis B and C, herpesviruses and pulmonary tuberculosis — or autoimmunity, from autoantibody markers after COVID-19 and antibodies to zinc transporter 8 to vitiligo, rheumatoid arthritis and catalytic autoantibodies in experimental autoimmune encephalomyelitis. Smaller groups of JOI papers look at how immune cells are regulated, including the role of the RNA methyltransferase METTL3 in immune homeostasis, at immunomodulatory and cell-based therapies such as adipose-derived stromal vascular fraction, and at cancer treatment outcomes. The journal publishes laboratory and clinical studies, case-control genetic association studies, Mendelian randomization analyses and narrative reviews, from circulating NETosis and pyroptosis markers measured in COVID-19 patients to peptide treatment in experimental tuberculosis. Case reports are accepted when an immunological question is at their centre. Every manuscript that passes the editorial check is reviewed double-blind. JOI articles are published open access under the Creative Commons Attribution licence (CC BY 4.0), and their authors keep the copyright. The journal follows the COPE guidelines on publication ethics; an article-processing charge applies only after acceptance, with need-based waivers and discounts.

Its published papers so far fall mainly into three areas: endourology and urinary stone disease, uro-oncology and urological pathology, and andrology and disorders of the male genital tract. AOU publishes original clinical studies and case reports, and also considers systematic reviews and meta-analyses reported to PRISMA. Recent examples include a comparison of anatomical changes on CT in the prone and supine positions in relation to percutaneous nephrolithotomy (PCNL), a retrospective analysis of risk factors for ureteric stricture after ureteroscopic lithotripsy, an observational study of endoscopic nephrolithotripsy for 1–2 cm renal stones in children, ISUP-graded cytology patterns in prostate fine-needle aspiration, and case reports of simultaneous bilateral testicular torsion and of Zinner's syndrome presenting as urinary retention in an adolescent. The journal suits urologists and urology trainees who want to report what they see in their own stone clinics, operating lists and tumour boards, from a single instructive patient to a retrospective series. Annals of Urology uses double-blind peer review for every manuscript it sends out. Its articles appear under a CC BY 4.0 licence, and their authors keep the copyright. Guided by COPE ethical principles, Annals of Urology aims to be a trusted, internationally accessible venue that advances urological evidence and practice while offering authors a transparent route to publication, with article-processing charges applied on acceptance and waivers or discounts available on request.